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Abstract
Background: We describe the serological response following H1N1-2009 influenza A infections confirmed by reverse-
transcriptase polymerase chain reaction (RT-PCR).
Methodology and Principal Findings: The study included patients admitted to hospital, subjects of a seroepidemiologic
cohort study, and participants identified from outbreak studies in Singapore. Baseline (first available blood sample) and
follow-up blood samples were analyzed for antibody titers to H1N1-2009 and recently circulating seasonal influenza A virus
strains by hemagglutination inhibition (HI) and virus micro-neutralization (VM) assays. 267 samples from 118 cases of H1N1-
2009 were analyzed. Geometric mean titers by HI peaked at 123 (95% confidence interval, CI 43-356) between days 30 to 39.
The chance of observing seroconversion (four-fold or greater increase of antibodies) was maximized when restricting
analysis to 45 participants with baseline sera collected within 5 days of onset and follow-up sera collected 15 or more days
after onset; for these participants, 82% and 89% seroconverted to A/California/7/2009 H1N1 by HI and VM respectively. A
four-fold or greater increase in cross-reactive antibody titers to seasonal A/Brisbane/59/2007 H1N1, A/Brisbane/10/2007
H3N2 and A/Wisconsin/15/2009 H3N2 occurred in 20%, 18% and 16% of participants respectively.
Conclusions and Significance: Appropriately timed paired serology detects 80–90% RT-PCR confirmed H1N1-2009;
Antibodies from infection with H1N1-2009 cross-reacted with seasonal influenza viruses.
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Introduction
The novel influenza A (H1N1-2009) virus first identified in April
2009 in the United States (US) and Mexico spread rapidly across
the world,[1,2,3] with Singapore experiencing its first wave of
infections from June to September 2009.[4] In Singapore and
elsewhere, serological surveys, using either hemagglutination
inhibition or virus neutralization, have been used to assess the
extent of H1N1-2009 infections.[5,6,7,8,9] Serological assays have
also been used to detect antibody responses against H1N1-2009 in
vaccine efficacy studies.[10,11,12]
Although hemagglutination inhibition assays have been widely
used to diagnose seasonal influenza and assess response to seasonal
influenza vaccines,[13,14] data is still needed to assess the
performance of such assays for pandemic H1N1-2009, the timing
of the serological response and the proportion of H1N1-2009 cases
which seroconvert. Recent work by Miller et al suggests that
detectable antibodies largely arise between 8 to 14 days after onset,
with more than 85% of subjects tested having antibody titers of 32
or greater by hemagglutination inhibition after 15 days.[7] Some
data has also been published on the sensitivity of paired serology
by hemagglutination inhibition and virus neutralization for
diagnosis of H1N1-2009, but the study involved a small number
of confirmed cases and did not take into account how the assay
might be affected by the timing of baseline and follow-up sample
collection.[15] In addition, there is also little data at present on the
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extent to which cross-reactive antibodies to other influenza A
strains develop following pandemic H1N1-2009 infection.
This study therefore aims to address the above knowledge gaps
by profiling the serological responses in a cohort of individuals
with naturally acquired H1N1-2009 infection confirmed by
reverse-transcriptase polymerase chain reaction (RT-PCR).
Methods
Objectives
We conducted an observational study to determine the optimal
timing of baseline and follow-up sample collection in a set of RT-
PCR-confirmed cases of pandemic H1N1-2009 influenza A
infections, estimate the sensitivity of paired serology by hemag-
glutination inhibition assays in detecting such cases while
accounting for the timing of paired samples, compare results
obtained with hemagglutination inhibition with those from virus
microneutralization assays, and assess if cross-reactive antibodies
to other influenza strains developed following infection with
H1N1-2009.
Participants
The study involved the collection of one or more blood samples
for serology from consenting participants in Singapore. For each
participant, we refer to the first blood sample as the ‘‘baseline’’
sample (even if collected after onset of illness), and all subsequent
samples as ‘‘follow-up’’ samples.
Participants enrolled in this study were drawn from 3 sources.
The first was from an observational study of patients admitted to
Tan Tock Seng Hospital (TTSH), Singapore. TTSH was the
designated facility for isolation and treatment of adult patients with
RT-PCR confirmed H1N1-2009 infection during the containment
phase of the Singapore epidemic.[16] Cases admitted to TTSH
were invited to participate in a clinical study to characterize the
infection. Consenting participants had a baseline blood sample
collected on the day of enrolment, and follow-up samples obtained
every other day thereafter during their admission. Following
discharge, participants were requested to return for follow-up
samples at 2–4 weeks and 6–8 weeks after the enrolment date. The
second source was from military personnel and hospital staff who
were part of a sero-incidence cohort study of pandemic H1N1-
2009 incidence.[17,18] Participants were enrolled before there was
widespread community transmission in Singapore and therefore
contributed their baseline blood samples prior to infection. Up to
two additional blood samples were collected during the first
epidemic wave. Participants who had RT-PCR confirmed H1N1-
2009 influenza A infection were included. The final source was
from participants identified during outbreak investigations in two
military camps (15 participants) and one long-term care facility (8
participants) who had had H1N1-2009 influenza A detected by
RT-PCR as well as serial blood samples which were collected in
the course of the investigations.
Participants also contributed information on demographics, past
medical history, influenza related symptoms, date of illness onset,
and details on oseltamivir treatment.
Laboratory confirmation of H1N1 infection by RT-PCR
For the diagnosis of influenza, nasal and throat samples
obtained with flocked swabs were transported in universal
transport medium (Copan) either to the Department of Laboratory
Medicine at TTSH or the DSO National Laboratories. Probe-
based RT-PCR was conducted with in-house or US Centers for
Disease Control and Prevention methods. [19]
Serological assays by hemagglutination inhibition and
virus neutralization
Both hemagglutination inhibition (HI) and virus microneutra-
lization (VM) assays were performed by the World Health
Organization Collaborating Centre for Reference and Research
on Influenza in Melbourne, Australia.
Details on the HI assays have been published elsewhere.[20]
These followed standard protocols with sera titrated in two-fold
dilutions from 1:10 to 1:1280 and tested against the A/California/
7/2009 (H1N1) pandemic virus. To investigate potential cross-
reaction by HI assay, a subset of samples was also tested against
three other influenza A strains. These were A/Brisbane/59/2007
H1N1 and A/Brisbane/10/2007 H3N2 (components of the 2009
Northern hemisphere seasonal influenza vaccine), and A/Wiscon-
sin/15/2009 H3N2 (an antigenic drift variant of H3N2 similar to
those circulating in Singapore in 2009 and which has since been
recommended as the updated H3N2 component to be included in
the trivalent seasonal influenza vaccines for the Southern
Hemisphere 2010 and Northern Hemisphere 2010-11 influenza
seasons).[21]
Virus microneutralization assays were performed on samples
with sufficient volume. Undiluted sera were inactivated by
incubation at 56uC for 30 min. Equal volumes of heat-treated
serum (at two-fold dilutions beginning at 1:10) and 100 tissue
culture infective dose (TCID)50 of the egg-propagated wild-type
A/California/7/2009 virus were mixed and incubated in
duplicate at 35uC for 1 hour. The virus-serum mix was then
added to washed, near-confluent (90%) monolayers of Madin-
Darby canine kidney cells (CCL-34, ATCC) in 96-well flat-
bottomed plates (Greiner Bio One) and incubated at 35uC with
5% CO2 for 2 h. The virus/serum mix was replaced with fetal-
calf-serum-free culture medium supplemented with 4 mg/ml
trypsin (Sigma) and the cells were incubated at 35uC with 5%
CO2. Four days later, supernatant from each well was assayed for
virus by a hemagglutination assay with 1% turkey erythrocytes.
Each titer was expressed as the reciprocal of the highest dilution of
serum where hemagglutination was prevented. Positive and
negative control human and animal sera as well as no serum
and no virus controls were included in each assay.
Ethics
Written informed consent was obtained from all participants.
The study was approved by the ethics review boards of the
National Healthcare Group, Singapore Armed Forces, National
University of Singapore and Australian National University.
Data analysis and statistical methods
Date of illness onset was based on the earliest reported
symptoms, except for 3 participants (2 sero-incidence cohort
participants and 1 outbreak case) without clear symptom onset
dates where the date of the positive RT-PCR test was used instead.
We then computed the time from illness onset to date of blood
sample collection to the nearest day. Seroconversion was defined
as a 4-fold or greater increase in antibody titer between the
baseline sample and follow-up blood sample for the same
individual. For participants with more than one follow-up sample,
the sample with the highest titer amongst all follow-up samples for
that participant was used to assess if seroconversion occurred. In
situations where the highest titer observed for a given participant
was found to occur in several follow-up samples for that
participant, the date of the latest follow-up sample was used when
investigating the effect of time from illness onset to follow-up
sample.
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Geometric mean titers (GMTs) were computed by assigning a
titer value of 5 for samples where antibodies were undetectable
(,10). In analyses where some individuals contributed more than
one observation, robust standard errors were used to construct
95% confidence intervals (CIs). Statistical testing was performed
with the level of significance set at p,0.05. For proportions, chi-
squared tests were used; for testing the relative change between
baseline and follow-up sample titers (i.e. the latter titer divided by
the former), we used the Wilcoxon rank-sum and Kruskal-Wallis
tests for binary and multichotomous variables respectively; for
comparing baseline and follow-up titers to different influenza
strains, the Wilcoxon signed-rank test for paired data was used. All
data was analyzed using STATA 10.0 (StataCorp, College Park,
Texas).
Results
Profile of study participants
Table 1 gives the characteristics of all 118 individuals included
in our study. The majority (57%, 67/118) were cases admitted to
TTSH, followed by participants from the sero-incidence cohort
study (24%, 28/118), and cases identified during outbreak
investigations (19%, 23/118). Since 25 of 28 participants from
the sero-incidence cohort and 15 of the 23 outbreak-related cases
were military personnel, there was a predominance of young males
in our study, with 69% (81/118) aged less than 35 years, and 71%
(84/118) being male. Asthma or bronchitis was reported by 12%
of all participants (14/118), with only a small number reporting
other co-morbid conditions. Most of the participants received
oseltamivir treatment (76%, 90/118), with 51% (46/90) receiving
treatment within 2 days or less of onset. There were a total of 267
blood samples from the 118 individuals (median of 2 per
participant). Due to incomplete follow-up, not all participants
provided complete sets of scheduled blood samples, but pair-wise
assessment of change in titers was possible in 90 (76%) participants
who contributed samples at two or more time points. A more
detailed breakdown on the contribution of hospitalized cases, sero-
incidence cohort participants and outbreak cases to the number of
individuals and samples analyzed is given in Table 2. Hospitalized
cases were less likely to have paired samples than sero-incidence
cohort participants and outbreak cases, but still accounted for the
majority of participants (50%, 45/90) with paired serology for
assessment.
Timing of serological response by hemagglutination
inhibition assays
Figure 1 shows antibody titers by time between onset and
sample collection, based on HI assays for all 267 samples.
Although antibodies could be detected in 6 of the 30 samples
(20%) collected before illness onset, none had titers of 40 or
greater. Within the first 14 days, the proportion with titers of 40 or
greater increased rapidly from 0% (0/65) on days 0–4, to 11% (5/
46) on days 5–9, 67% (6/9) on days 10–14, and 80% (8/10) on
days 15–19, with a corresponding increase in the geometric mean
titer. Beyond day 15, the increase in titers was more gradual; the
proportion with titers of 40 or greater peaked at 93% (14/15)
between days 25–29, and GMT was highest in samples collected
between days 30–39 (123, 95% CI 43 to 356).
Overall, seroconversion was observed in 53 of the 90
participants with two or more samples (59%, 95% CI 49% to
68%). Seroconversion percentages varied by the timing of the
baseline and follow-up samples relative to illness onset (Figure 2).
The chance of observing seroconversion was maximized at 82%
(95% CI 69% to 91%) when the analysis was restricted to the 45
participants where the baseline sample was collected earlier (before
onset or less than 5 days from illness onset), and the follow-up
sample collected later (15 days or more days after illness onset). To
reduce potential confounding by time of sample collection, we
restricted to this subset of 45 participants when analyzing for
associations between seroconversion and other participant char-
acteristics.
Comparison of hemagglutination inhibition and virus
microneutralization
Figure 3A compares baseline titers obtained using HI and VM
assays, restricted again to the 45 participants with optimally
timed baseline and follow-up samples. No detectable antibodies
(titers,10) were observed in 84% (38/45) by HI assay compared
to 100% (45/45) by VM. Figure 3B compares follow-up sample
titers in 45 participants by HI, and in 44 participants by VM
assays (one sample was not tested by VM due to insufficient sera).
While the distribution derived from the two tests was fairly
similar, follow-up GMTs were 59 (95% CI 41-85) by HI
compared to 47 (95% CI 32-68) by VM assay, the difference
Table 1. Characteristics of study participants (N= 118).
Participant characteristics
Source Hospitalized cases 67 (57)
Seroincidence cohort 28 (24)
Outbreak cases 23 (19)
Age distribution in years Median (range) 25 (19–62)
,20 years 8 (7)
20–34 years 73 (62)
35–49 years 19 (16)
$50 years 18 (15)
Gender Male 84 (71)
Female 34 (29)
Co-morbid conditions Asthma or bronchitis 14 (12)
Hypertension or dyslipidemia 9 (8)
Cardiovascular disease 2 (2)
Diabetes mellitus 4 (3)
Cancer and immunological
disorders*
8 (7)
Oseltamivir treatment Yes 90 (76)
No 23 (19)
Unknown 5 (4)
Onset to oseltamivir
treatment
Timing unknown 9 (10){
2 days or less 46 (51){
3 or more days 35 (39){
Number of samples Median (range) 2 (1–7)
One 28 (24)
Two 46 (39)
Three or more 44 (37)
NB: Unless otherwise stated, data presented are number of participants with
percentages in brackets.
*Hodgkin’s lymphoma in remission, leukemia in remission, breast cancer on
tamoxifen, human immunodeficiency virus infection on antiviral treatment,
sarcoidosis, rheumatoid arthritis, systemic lupus erythematosus, long-term
prednisolone therapy for unspecified endocrine disorder.
{As % of subjects who received oseltamivir treatment.
doi:10.1371/journal.pone.0012474.t001
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being of borderline significance (p = 0.06 by Wilcoxon signed-
rank test on 44 observations). Figure 3C shows the effect of using
different cut-off points for defining seroconversion. Almost all
participants had some detectable increase in titers, with 96% (43/
45) having a two-fold or greater increase in titer by HI compared
to 98% (43/44) by VM. When using the traditionally accepted
cut-off point of a four-fold or greater increase in titers, 82% (37/
45) were classified as having seroconverted by HI, which was
slightly less than the 89% (39/44) by the VM assay. However,
because a greater proportion of participants had follow-up titers
of 40 or greater by HI than by VM, 71% (32/45) had an 8-fold or
greater increase in titers by HI compared with only 57% (25/44)
by VM.
We also investigated if the probability of observing seroconver-
sion on HI or VM assays was associated with various participant
characteristics. Notably, seroconversion was not significantly
associated with treatment or timing of treatment with oseltamivir,
nor with age, gender, co-morbidities and baseline antibody titers;
the relative change between baseline and follow-up titers were also
not affected by any of these participant characteristics.
Cross-reactive antibodies detected on hemagglutination
inhibition assays
Investigation of cross-reactive serological response on hemag-
glutination inhibition was also restricted to the same subset of 45
participants with optimally timed baseline and follow-up samples.
Table 3 shows titers in baseline and follow-up samples to
pandemic H1N1-2009 (A/California/7/2009 H1N1) and three
seasonal influenza A strains. None of the participants had titers of
40 or greater to A/California/7/2009 H1N1 in their baseline
samples, whereas 42% (19/45), 24% (11/45) and 18% (8/45)
exhibited titers of 40 or greater to A/Brisbane/59/2007 H1N1,
A/Brisbane/10/2007 H3N2 and A/Wisconsin/15/2009 H3N2
respectively. GMT in the baseline sample was highest for A/
Brisbane/59/2007 H1N1 (18, 95% CI 12-26), but lowest for A/
California/7/2009 H1N1 (6, 95% CI 5-6). GMTs to all four
strains increased in follow-up samples, but the increase was
statistically significant only for A/California/7/2009 H1N1 and
A/Brisbane/59/2007 H1N1 (p,0.01 for both). Interestingly,
seroconversion to A/Brisbane/59/2007 H1N1, A/Brisbane/10/
2007 H3N2 and A/Wisconsin/15/2009 H3N2 occurred in 9
Table 2. Detailed breakdown on sources of study participants and samples.
Hospitalized cases Sero-incidence cohort Outbreak cases Total
All participants No. of participants 67 (57) 28{ (24) 23{ (19) 118 (100)
No. of samples 148 (55) 76 (28) 43 (16) 267 (100)
Two or more samples No. of participants 45 (50) 28 (31) 17 (19) 90 (100)
No. of samples 126 (53) 76 (32) 37 (15) 239 (100)
NB: Numbers in brackets are row percentages.
{25 military personnel and 3 hospital staff from Tan Tock Seng Hospital.
{15 participants from military outbreaks and 8 from the long-term care facility outbreak.
doi:10.1371/journal.pone.0012474.t002
Figure 1. Hemagglutination inhibition titers by time from illness onset to sample collection. Includes 267 samples from 118 individuals.
Samples taken before onset in sero-incidence cohort participants are grouped (as ,0* days), as are those taken after 70 days ($70 days), with other
observations summarized in 5 day intervals up to 29 days, 10 day intervals from 30 to 69 days. The number of samples in each interval is in brackets;
intervals marked with# include 7 samples from the 3 individuals whose date of positive PCR test was used instead of onset dates:,0 (2 samples), 20
to 24 (1 sample), 40 to 49 (2 samples) and $70 (2 samples). Colored stacked bars give the proportion with titers of 10, 20, 40 and $80 while the line
denotes the geometric mean titer with error bars depicting 95% confidence intervals. The upper limit is off the scale for days 10–14 (518) and days
30–39 (356).
doi:10.1371/journal.pone.0012474.g001
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(20%), 8 (18%) and 7 (16%) participants, all of whom also
seroconverted to A/California/7/2009 H1N1.
Discussion
There is currently limited data on the antibody response
following H1N1-2009 infection as detected on serological assays.
In our study, antibody titers increased rapidly in the first 2 weeks,
and collection of acute samples less than 5 days from illness onset,
and convalescent samples more than 2 weeks after illness onset,
maximized the proportion of RT-PCR confirmed infections which
seroconverted on hemagglutination inhibition assays. In addition,
we showed that more than 80% of RT-PCR confirmed H1N1-
2009 cases seroconvert using hemagglutination inhibition and
virus microneutralization assays, and demonstrated the develop-
ment of cross-reactive antibodies to other influenza A strains
following H1N1-2009 infection. These key characteristics of the
antibody response have implications on the interpretation of
serological assays for pandemic H1N1-2009.
Our finding, on the rapid increase of detectable antibodies by
hemagglutination inhibition in the first two weeks, is fairly similar
to what Miller and colleagues observed.[7] In addition to what
they found, we were able to demonstrate how the timing of the
blood sampling with respect to symptom onset affects the
characteristics of paired serological assays. To optimize assay
performance, we found that convalescent sera should be collected
at least 2 weeks after illness onset. Testing samples collected less
than 5 days after onset of illness maximized the proportion
observed to seroconvert, although the cut-off point for acute sera
was less critical. We also demonstrated that, with appropriately
timed samples, 82% and 89% of the RT-PCR confirmed cases
seroconverted on the HI and VM assays respectively. These results
are fairly close to those described by Cowling et al, who reported
that slightly less 80% and more than 95% of 19 RT-PCR
confirmed pandemic H1N1-2009 cases with paired serology had
four-fold or greater increase in titers on HI and VM assays
respectively.[15] However, unlike Cowling who suggested that
subjects given oseltamivir treatment early in the course of their
disease might have a diminished convalescent antibody response,
we did not find this to be so for oseltamivir use, nor for any of the
participant characteristics investigated. It must be noted, however,
that our study was under-powered to investigate key features of
importance, such as co-morbid conditions which might depress
immune function since such subjects were under-represented in
our study.
Finally, we also documented the development of cross-reactive
antibodies to other strains of influenza A following RT-PCR
confirmed H1N1-2009 infection. While we cannot rule out the
possibility that recent H3N2 or seasonal H1N1 infections
preceding the episode of H1N1-2009 infection might have
accounted for some of our findings, we note that there was little
circulation of seasonal H1N1viruses throughout the study period,
and H3N2 activity had also largely waned by the time our H1N1-
2009 cases were sampled.[22] Heterotypic cross-reactive antibod-
ies following suspected infection with pandemic influenza strains
have been previously reported. For instance, one study on the
1968 influenza pandemic in Singapore reported that some pa-
tients with clinically diagnosed influenza who seroconverted to A/
Singapore/1/68 (H3N2), the pandemic strain circulating in Singa-
pore then, also seroconverted to A/Singapore/1/57 (H2N2),
the causative strain of the previous pandemic about a decade
earlier.[23] It is unclear as to the extent these cross-reactive
antibodies are protective to the respective influenza A strains in
vivo, but such antibodies could be one pathway for the heterotypic
protection observed in an epidemiological study which showed
how adults previously infected with H1N1 influenza in the years
prior to the 1957 pandemic were protected during the 1957 H2N2
pandemic.[24] Our observations on cross-reactive antibodies also
have implications for interpreting data from serologic surveys
which assess relative infection rates of H3N2 and H1N1-2009
while the two strains continue to co-circulate.
Limitations
Our study was based on participants aggregated from three
separate sources which differed in their population characteris-
tics and timing of sample collection. Due to low follow-up rates
for the 2 to 4 week and 6 to 8 week samples, hospitalized cases
were overrepresented in earlier samples and underrepresented in
later samples. We suggest that the main bias that would arise
from aggregating such subjects for analysis relates to the
differences in the timing of baseline and follow-up samples for
the three different groups, and we hence attempted to reduce
such biases by restricting analyses to participants with baseline
and follow-up sera collected within an appropriate time-frame.
However, in doing so, the study sample size available for
detecting differences in serological response by participant
characteristics was reduced.
Figure 2. Seroconversion on hemagglutination inhibition
assay, by timing of sample collection. Titers between baseline
and follow-up (FU) sample is compared, for all participants regardless of
time from onset to follow-up sample (n = 90), and restricting to
participants whose follow-up sample was taken 15 or more days after
onset (n = 68), with error bars depicting 95% confidence intervals;
columns of different colors depict different cut-off points for time from
onset to baseline sample. Seroconversion was defined here as a four-
fold or greater increase in antibody titer.
doi:10.1371/journal.pone.0012474.g002
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Conclusions
In spite of the above limitations, our study provides important
information profiling key aspects of the serological response
following infection with the pandemic H1N1-2009 strain. Our
findings also have implications for the serological diagnosis of
H1N1-2009 based on paired serum samples, as well as the conduct
of future serological surveys for influenza. Further studies are
needed to understand the significance and mechanisms of the
cross-reactive antibody responses to other influenza strains that
occur in some individuals following H1N1-2009 infection.
Figure 3. Comparison between hemagglutination inhibition (HI) and virus neutralization (VM). A) baseline sample titers (n = 45 for HI,
n = 45 for VM); B) follow-up sample titers (n = 45 for HI, n = 44 for VM); C) fold rise in titer for follow-up relative to baseline titer (n = 45 for HI, n = 44 for
VM). In all three panels, lines denote the reverse cumulative distribution with error bars representing the 95% confidence intervals.
doi:10.1371/journal.pone.0012474.g003
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Table 3. Hemagglutination inhibition titers and seroconversion to different influenza A strains (N= 45).
Antibody titers, %
Strain Sample ,10 10–20 $40 GMT (95% CI) p-value* SC{, % (95% CI)
A/California/7/2009 H1N1 (pandemic) Baseline 84 16 0 6 (5–6) - -
Follow-up 4 18 78 59 (41–85) ,0.01 82 (69–91)
A/Brisbane/59/2007 H1N1 (seasonal) Baseline 40 18 42 18 (12–26) - -
Follow-up 29 11 60 36 (23–59) ,0.01 20 (11–34)
A/Brisbane/10/2007 H3N2 (seasonal) Baseline 40 36 24 15 (10–22) - -
Follow-up 36 24 40 20 (13–30) 0.80 18 (9–31)
A/Wisconsin/15/2009 H3N2 (seasonal) Baseline 67 16 18 10 (7–14) - -
Follow-up 60 7 33 13 (9–20) 0.43 16 (8–29)
*Wilcoxon signed-rank test comparing baseline and follow-up titers.
{SC: seroconversion (4-fold or greater increase in titer).
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